

## METANX® Capsules

A medical food for the dietary management of diabetic peripheral neuropathy and diabetic ulcer.

### DESCRIPTION

Each opaque caramel/white capsule contains:

#### Dietary Ingredients:

L-methylfolate Calcium (Metafolin®)	3mg
Algae S Powder (Schizochytrium)	90.314mg
Pyridoxal-5'-Phosphate	35 mg
Methylcobalamin	2 mg

#### Other Ingredients:

Silicified Microcrystalline Cellulose 90, Algae-S Powder (Schizochytrium Algal Oil [Vegetable source]), Glucose Syrup Solids, Mannitol, Sodium Caseinate, Soy Protein, High Oleic Sunflower Oil, Sodium Ascorbate, Natural Flavors, Tricalcium Phosphate, Tetrasodium Diphosphate, Tocopherols, Soy Lecithin, Ascorbyl Palmitate), Pullulan, Pyridoxal-5-Phosphate, L-methylfolate Calcium, Methylcobalamin, Titanium Dioxide, Magnesium Stearate, Caramel 1, Riboflavin, N-Butyl Alcohol, Isopropyl Alcohol, Propylene Glycol, Shellac.

**METANX® capsules contain milk and soy.**

### INDICATIONS AND USAGE

#### CLINICAL DIETARY MANAGEMENT OF DIABETIC PERIPHERAL NEUROPATHY

METANX® is indicated for the distinct nutritional requirements of individuals with endothelial dysfunction who present with loss of protective sensation and neuropathic pain associated with diabetic peripheral neuropathy.<sup>1-6</sup>

### ADVERSE REACTIONS

Allergic reactions have been reported following the use of oral L-methylfolate Calcium.<sup>13</sup> Acne, skin reactions, allergic reactions, photosensitivity, nausea, vomiting, abdominal pain, loss of appetite, increased liver function test results, paresthesia, somnolence, nausea, and headaches have been reported with pyridoxal 5'-phosphate.<sup>14</sup> Mild transient diarrhea, itching, transitory exanthema and the feeling of swelling of the entire body has been associated with methylcobalamin.<sup>15</sup>

### CONTRAINDICATIONS

METANX® is contraindicated in patients with known hypersensitivity to any of the components contained in this product.

### PATIENT INFORMATION

METANX® is a medical food for use under medical supervision.

### RECOMMENDED USE

Usual adult dose may be taken as one capsule twice daily (1capsules B.I.D.); or two capsules once daily (2 capsules QD) or as directed under medical supervision.

### HOW SUPPLIED

Commercial Product (90 capsules)	
00525-8049-90	Rx
Commercial Product (180 capsules)	
00525-8049-18	Rx
Professional Sample (6 capsules)	
00525-8049-06	Not for Sale

Available as an opaque caramel capsule and opaque white body. It is imprinted with "Metanx" in red ink on the body.

## CLINICAL DIETARY MANAGEMENT OF DIABETIC ULCER

METANX<sup>®</sup> is indicated for the distinct nutritional requirements of patients with endothelial dysfunction and/or hyperhomocysteinemia who present with lower extremity ulceration(s).<sup>7-10, 16</sup>

### PRECAUTIONS

Folic acid, when administered in daily doses above 0.1mg, may obscure the detection of B12 deficiency (specifically, the administration of folic acid may reverse the hematological manifestations of B12 deficiency, including pernicious anemia, while not addressing the neurological manifestations). L-methylfolate Calcium may be less likely than folic acid to mask vitamin B12 deficiency.<sup>11,12</sup> Folate therapy alone is inadequate for the treatment of a B12 deficiency.

### STORAGE

Store at controlled room temperature 15°C to 30°C (59°F to 86°F) (See USP). Protect from heat, light and moisture.

Metafolin<sup>®</sup> is a trademark of Merck KGaA, Germany

Manufactured and Distributed by  
Alfasigma USA, Inc.  
Shreveport, LA 71103

Questions?  
Call 1-844-639-9726

## REFERENCES

1. Verhaar M.C., et al. *Circulation* 1998;97:237-241.
2. Van Etten R.W., et al. *Diabetologia* 2002;45:1004-1010.
3. Romerio S.C., et al. *Atherosclerosis* 2004;176:337-344.
4. Walker MJ Jr, et al. *Rev Neurol Dis* 2010;7(4):132-139.
5. Jacobs AM, Cheng D. *J Diabetes Mellitus*. 2013;3(3):134-138.
6. Li G. Beijing Methylcobal Clinical Trial Collaborative Group. *Zhonghua Nei Ke Za Zhi* 17
7. Ambrosch A. et al. *Diabet Med*. 2001;18:185-192.
8. Veves A., et al. *Diabetes* 1998;47:457-463.
9. Boykin J.V. Jr. *Vascular Disease Management* 2007;2(1):1-8.
10. Boykin J.V. Jr., Byalis C. *Wounds* 2006;18(4):101-116.
11. B Akoglu, et al. *European Journal of Clinical Nutrition* (2007), 1-6.
12. Scott JM, et al. *Lancet*. 1981 2:337-340.
13. Natural Standard Research Collaboration (NIH). *Folate (folic acid) Monograph* 2009.
14. *Alternative Medicine Review Vitamin B6 Monograph Volume 6, Number 1, 2001.*
15. Natural Standard Research Collaboration (NIH). *Vitamin B12 Monograph* 2009.
16. Boykin J.V. Jr. *Wound Rep Reg* 2020;28:517-525

Revised {01/2024}